10-Q: Cibus Inc. Reports Third Quarter 2024 Results, Announces Strategic Realignment

Cibus Inc. reported a net loss of $201.5 million for the third quarter of 2024, including a significant goodwill impairment, and announced a strategic realignment to focus on commercialization.

Summary

• Cibus Inc. reported a net loss of $201.5 million for the third quarter of 2024, compared to a net loss of $34.5 million in the same period of 2023.
• The company's revenue for the quarter was $1.7 million, up from $0.5 million in the third quarter of 2023, primarily due to collaboration agreements.
• Research and development expenses decreased to $13.0 million from $17.5 million year-over-year, while selling, general, and administrative expenses decreased to $7.7 million from $8.8 million.
• A significant goodwill impairment of $181.4 million was recorded in the third quarter of 2024.
• The company's royalty liability interest expense increased to $8.9 million from $8.1 million year-over-year.
• Cibus announced a strategic realignment in October 2024, including a workforce reduction of approximately 26 full-time employees, expected to save approximately $10 million annually.
• The company expects its existing cash and cash equivalents to fund operations into late in the first quarter of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in technology and commercialization, the significant net loss, goodwill impairment, and going concern warning weigh heavily on the sentiment. The strategic realignment and cost-cutting measures are a necessary step, but the company's financial position remains precarious.

Positives

• Revenue increased significantly year-over-year, driven by collaboration agreements.
• Research and development expenses decreased year-over-year due to cost-cutting measures.
• The company is making progress in its trait transfer process for its HT1 and HT3 traits in Rice.
• Cibus has completed a successful field trial with one of its customer's germplasm in the third quarter of 2024.
• The company has completed an initial field trial for its PSR trait in WOSR in the United Kingdom.
• Cibus is advancing its Sclerotinia resistance trait in Canola and Soybean.
• The company has received additional patents across 10 plant gene editing and trait families.

Negatives

• The company reported a significant net loss of $201.5 million for the third quarter of 2024.
• A substantial goodwill impairment of $181.4 million was recorded in the third quarter of 2024.
• The company's royalty liability interest expense increased year-over-year.
• Cibus' cash and cash equivalents are not sufficient to fund operations for a period of 12 months or more from the date of this filing.
• The company expects its existing cash and cash equivalents to fund operations into late in the first quarter of 2025.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• If the company is unable to raise additional capital, it may have to implement more stringent cost reduction measures or cease operations.
• The company's financing needs are subject to change depending on the success of its trait and product development efforts.
• Macroeconomic events and potential geopolitical developments may make obtaining capital more challenging.
• The company's future success depends on the adoption of its traits by farmers and seed companies.
• Regulatory developments could disfavor or impose significant burdens on gene editing processes or products.

Future Outlook

The company expects its existing cash and cash equivalents to fund operations into late in the first quarter of 2025. Cibus will need to raise additional capital to support its business plans to continue as a going concern within one year after the date that these financial statements are issued.

Management Comments

• Cibus is transforming from a Research and Development (R&D) driven organization to a focused commercial stage gene editing company in agriculture.
• Cibus believes that its RTDS technologies and Trait Machine process represent a paradigm shift in plant breeding.
• Cibus believes that its gene editing technologies and trait products have the potential to accelerate agricultures jump to a climate smart, more sustainable, crop production system.
• Cibus is focusing its capital resources toward its commercial effort priorities through advancement of Cibus' weed management traits HT1 and HT3 for Rice, Sclerotinia resistance trait for Soybean and Canola, and the continuing development of Cibus' Soybean platform.

Industry Context

The report highlights the evolving regulatory landscape for gene editing technologies, with major markets moving towards treating gene-edited traits similarly to those developed through conventional breeding. This shift is crucial for Cibus, as it positions its technology as a more acceptable alternative to GMOs, particularly in regions like the EU where GMOs have faced significant regulatory hurdles.

Comparison to Industry Standards

• The company's focus on gene editing for productivity traits aligns with the broader industry trend towards sustainable agriculture and improved crop yields.
• Cibus's RTDS platform and Trait Machine process are presented as a unique approach to high-throughput gene editing, differentiating it from traditional breeding methods and other gene editing companies.
• The company's progress in developing herbicide tolerance and disease resistance traits is comparable to other companies in the agricultural biotechnology sector, but its focus on direct editing into elite germplasm is a key differentiator.
• The company's financial performance, particularly the significant net loss and goodwill impairment, is a concern and may be worse than some of its peers in the industry, especially those with commercialized products.

Related Party Transactions

• Cellectis, the Company's largest shareholder prior to the completion of the Merger Transactions, has guaranteed the lease agreement for the Companys Roseville, Minnesota facility.
• The Company agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease, effective upon Cellectis ownership falling to 50 percent or less of the Companys outstanding common stock.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and going concern warning.
• Employees have been impacted by the workforce reduction.
• Customers may be affected by the company's strategic realignment and focus on specific traits.
• Suppliers and creditors may be impacted by the company's financial challenges and cost-cutting measures.

Next Steps

• The company will continue to advance its weed management traits HT1 and HT3 for Rice, Sclerotinia resistance trait for Soybean and Canola, and the continuing development of Cibus' Soybean platform.
• The company will continue to opportunistically pursue partner-funded projects.
• The company will implement cost reduction actions to reduce monthly cash use by approximately 20 percent.
• The company will seek additional capital to support its business plans.

Key Dates

Keywords

gene editing, plant traits, agriculture, biotechnology, crop productivity, RTDS, trait development, herbicide tolerance, disease resistance, soybean, canola, rice, commercialization, strategic realignment, cost reduction